Drug Trial Radar · NCT00000134
Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
Last checked: Nov 19, 2026Latest source record: Sep 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
279
Actual
Start
Dec 1992
Primary completion
Mar 1995
Study completion Mar 1995
Sponsor
- Lead sponsor
- Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Eye Institute (NEI); National Institute of Allergy and Infectious Diseases (NIAID); Johns Hopkins University; University of Wisconsin, Madison; Baylor College of Medicine; Tulane University School of Medicine; Icahn School of Medicine at Mount Sinai; New York Presbyterian Hospital; New York University; Northwestern University; University of California, Los Angeles; University of California, San Francisco; University of California, San Diego; University of Miami; University of North Carolina, Chapel Hill; Memorial Sloan Kettering Cancer Center
- First posted
- Sep 24, 1999
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.
Conditions
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Cytomegalovirus Retinitis
Interventions
GanciclovirDrug
intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
FoscarnetDrug
intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- MorbidityTime frame: Patients will be seen at baseline, monthly for six months, and then every three months until death or termination of the trial
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.